Clinical Trials Browser

Phase 2 × entrectinib × 90 days × Clear all

NCT02568267 2026-05-27

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04302025 2026-05-22

NAUTIKA1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06528691 2026-05-13

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

Glioma, Central Nervous System Neoplasms

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT03994796 2026-04-13

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Phase 2 Active not recruiting

Brain Neoplasms, Neoplasm Metastasis